Bicara Therapeutics Inc (BCAX)

May 05, 2025

Invesco Ltd. Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

May 05, 2025

May 03, 2025

Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.43 - Defense World

May 03, 2025

May 02, 2025

A new trading data show Bicara Therapeutics Inc (BCAX) is showing positive returns. - Sete News

May 02, 2025

May 02, 2025

Legal & General Group Plc Acquires New Holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

May 02, 2025

May 01, 2025

Bicara Therapeutics Inc [BCAX] Shares Fall -3.43 % on Wednesday - knoxdaily.com

May 01, 2025

May 01, 2025

A closer look at Bicara Therapeutics Inc (BCAX)’s stock price trends - uspostnews.com

May 01, 2025

May 01, 2025

Wedbush Lifts Earnings Estimates for Bicara Therapeutics - Defense World

May 01, 2025

Apr 30, 2025

Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa Drives Buy Rating Amid Encouraging Clinical Data and Growth Opportunities - TipRanks

Apr 30, 2025

Apr 29, 2025

Cautious Outlook on Bicara Therapeutics Inc. Amid Efficacy and Safety Concerns for Ficerafusp - TipRanks

Apr 29, 2025

Apr 29, 2025

Promising Clinical Trial Results Boost Buy Rating for Bicara Therapeutics - TipRanks

Apr 29, 2025

Apr 28, 2025

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 - GlobeNewswire

Apr 28, 2025

Apr 28, 2025

Riding the Waves: A Guide to Investing in BCAX Stock - investchronicle.com

Apr 28, 2025

Apr 28, 2025

JPMorgan Chase & Co. Buys 64,010 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Apr 28, 2025

Apr 27, 2025

Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Here’s Why - Defense World

Apr 27, 2025

Apr 24, 2025

Bicara Therapeutics Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com

Apr 24, 2025

Apr 24, 2025

Bicara Therapeutics Inc (NASDAQ: BCAX) Is The Among Hot Stock Right Now - Stocksregister

Apr 24, 2025

Apr 24, 2025

Geode Capital Management LLC Acquires 418,003 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Apr 24, 2025

Apr 23, 2025

Bicara to present updated trial data at ASCO Meeting - Investing.com

Apr 23, 2025

Apr 23, 2025

Bicara to present updated trial data at ASCO Meeting By Investing.com - Investing.com South Africa

Apr 23, 2025

Apr 23, 2025

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times

Apr 23, 2025

Apr 23, 2025

Bicara Therapeutics to Present Updated Phase 1/1b Clinical Trial Data for Ficerafusp Alfa at ASCO 2025 - Nasdaq

Apr 23, 2025

Apr 20, 2025

Bicara Therapeutics (NASDAQ:BCAX) Research Coverage Started at Wells Fargo & Company - The AM Reporter

Apr 20, 2025

Apr 19, 2025

Bicara Stock: Innovative Precision Tumor Targeting (NASDAQ:BCAX) - Seeking Alpha

Apr 19, 2025

Apr 19, 2025

Wells Fargo & Company Initiates Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World

Apr 19, 2025

Apr 18, 2025

Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN

Apr 18, 2025

Apr 17, 2025

Vanguard Group Inc. Acquires 1,020,528 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Apr 17, 2025

Apr 17, 2025

Bicara Therapeutics initiated with an Underweight at Wells Fargo - TipRanks

Apr 17, 2025

Apr 17, 2025

This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Apr 17, 2025

Apr 17, 2025

Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target - marketscreener.com

Apr 17, 2025

Apr 14, 2025

Corebridge Financial Inc. Takes $167,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Apr 14, 2025

Apr 11, 2025

HC Wainwright Issues Pessimistic Forecast for BCAX Earnings - Defense World

Apr 11, 2025

Apr 10, 2025

Promising Developments and Market Opportunities Drive Buy Rating for Bicara Therapeutics - TipRanks

Apr 10, 2025

Apr 09, 2025

HC Wainwright Issues Pessimistic Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price - The AM Reporter

Apr 09, 2025

Apr 08, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $36.67 Average Target Price from Brokerages - Defense World

Apr 08, 2025

Apr 08, 2025

Bicara Therapeutics (NASDAQ:BCAX) Given New $44.00 Price Target at HC Wainwright - Defense World

Apr 08, 2025

Apr 07, 2025

Bicara stock price target lowered to $44 at H.C. Wainwright By Investing.com - Investing.com Canada

Apr 07, 2025

Apr 07, 2025

Bicara stock price target lowered to $44 at H.C. Wainwright - Investing.com

Apr 07, 2025

Apr 07, 2025

Buy Rating Affirmed for Bicara Therapeutics Inc. Amid Promising Clinical Data and Financial Stability - TipRanks

Apr 07, 2025

Apr 07, 2025

Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 3.2%Should You Sell? - MarketBeat

Apr 07, 2025

Apr 03, 2025

FY2025 EPS Estimates for BCAX Raised by Cantor Fitzgerald - Defense World

Apr 03, 2025

Mar 31, 2025

Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock - Investing.com

Mar 31, 2025

Mar 31, 2025

Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock By Investing.com - Investing.com UK

Mar 31, 2025

Mar 31, 2025

Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics - TipRanks

Mar 31, 2025

Mar 31, 2025

Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst - Defense World

Mar 31, 2025

Mar 29, 2025

Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World

Mar 29, 2025

Mar 28, 2025

Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Mar 28, 2025

Mar 28, 2025

Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada

Mar 28, 2025

Mar 28, 2025

Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Progress and Strong Financial Position - TipRanks

Mar 28, 2025

Mar 28, 2025

Bicara Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks

Mar 28, 2025

Mar 27, 2025

Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı

Mar 27, 2025

Mar 27, 2025

Stifel raises Bicara stock price target to $48, maintains Buy - Investing.com India

Mar 27, 2025